Five things for pharma marketers to know: Monday, April 30, 2018

Share this content:

Allergan's migraine drug met its endpoints in a Phase III trial, reducing pain and eliminating bothersome symptoms in a statistically significant percentage of patients. The company plans to file for approval next year. (Reuters)


WPP's health and wellness, brand consulting, and specialist communications division reported a 2% revenue increase in the first quarter to $1.5 billion. In the holding company's first earnings call since CEO Martin Sorrell resigned, co-COO Mark Read said WPP is not planning to sell off its assets en masse, but could rid itself of underperforming units (MM&M)


OrbiMed Advisors founder Sam Isaly has left the biotech hedge fund. The move comes more than four months after he was accused of sexual harassment by six former employees. (STAT)


The FDA has agreed to give Regeneron/Sanofi's PD-1/L1 checkpoint inhibitor to treat metastatic cutaneous squamous cell carcinoma a priority review, with a PDUFA date of October 28. If approved, it would be the 6th PD-1/L1 checkpoint inhibitor on the market. (Endpoints News)


Democrats and watchdog groups are scrutinizing the salary of CDC director Dr. Robert Redfield, who was appointed to the role in March. Redfield's salary, at $375,000, is nearly twice as much as some predecessors and substantially more than other government agency directors. (New York Times)
Share this content:
Scroll down to see the next article